An update on the first decade of the European centralized procedure: How many innovative drugs?

British Journal of Clinical Pharmacology

Volumn 62, Issue 5, 2006, Pages 610-616

  Motola, Domenico ^a   De Ponti, Fabrizio ^a,c   Poluzzi, Elisabetta ^a   Martini, Nello ^b   Rossi, Pasqualino ^b   Silvani, Maria Chiara ^a   Vaccheri, Alberto ^a   Montanaro, Nicola ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ITALIAN MEDICINES AGENCY   (Italy)

^c Department of Pharmacology ^*  (Italy)

Author keywords

Biotechnological drugs; Drug approval; Drug evaluation; European centralized procedure; Therapeutic innovation

Indexed keywords

ADALIMUMAB; ANTIINFECTIVE AGENT; ANTINEMATODAL AGENT; ANTIPARASITIC AGENT; BOTULINUM TOXIN B; CARDIOVASCULAR AGENT; CARGLUMIC ACID; CLOPIDOGREL; DERMATOLOGICAL AGENT; DOXORUBICIN; DRUG; ERTAPENEM; GASTROINTESTINAL AGENT; HEMATOLOGIC AGENT; HORMONE; IBANDRONIC ACID; IBUPROFEN; IMIQUIMOD; LEPIRUDIN; PACLITAXEL; RALOXIFENE; RAPAMYCIN; RECOMBINANT HUMAN INSULIN; RETEPLASE; TOLCAPONE; UNINDEXED DRUG; VACCINE; VALDECOXIB; ZALEPLON; ZOLEDRONIC ACID;

ALGORITHM; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BIOTECHNOLOGICAL PRODUCTION; DRUG APPROVAL; DRUG INDUSTRY; DRUG SCREENING; EUROPE; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL;

DRUG APPROVAL; EUROPEAN UNION; HUMANS; LEGISLATION, DRUG; RETROSPECTIVE STUDIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 33749987748     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02700.x     Document Type: Article

References (22)

1. The Council of the European Communities. Council Regulation (EEC) no. 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products. Regulation (EEC) No. 2309/93.
2. Garattini S, Bertelé V. Efficacy, safety and cost of new cardiovascular drugs: a survey. Eur J Clin Pharmacol 2003; 59: 701-6.
3. Garattini S, Bertelé V. Efficacy, safety and cost of new drugs acting on the central nervous system. Eur J Clin Pharmacol 2003; 59: 79-84.
4. Garattini S, Bertelé V. Efficacy, safety, and cost of new anticancer drugs. BMJ 2002; 325: 269-71.
5. Motola D, De Ponti F, Rossi P, Martini N, Montanaro N. Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol 2005; 59: 475-8.
6. Aronson JK. Drug development: more science, more education. Br J Clin Pharmacol 2005; 59: 377-8.
7. Ball P. Adverse drug reactions. implications for the development of fluoroquinolones. J Antimicrob Chemother 2003; 51 (Suppl. 1): 21-7.
8. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-85.
9. Frank RG. New estimates of drug development costs. J Health Econ 2003; 22: 325-30.
10. Cech TR. Fostering innovation and discovery in biomedical research. JAMA 2005; 294: 1390-3.
11. EMEA. European Public Assessment Report on Fabrazyme. http://www.emea.eu.int/humandocs/Humans/EPAR/fabrazyme/fabrazyme.htm2004 (last accessed: 24 February 2006).
12. EMEA. European Public Assessment Report on Replagal. http://www.emea.eu. int/humandocs/Humans/EPAR/replagal/replagal.htm2004 (last accessed: 24 February 2006).
13. Guffon N, Fouilhoux A. Clinical benefit in Fabry patients given enzyme replacement therapy - a case series. J Inherit Metab Dis 2004; 27: 221-7.
14. Clarke JT, Iwanochko RM. Enzyme replacement therapy of Fabry disease. Mol Neurobiol 2005; 32: 43-50.
15. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005; 20: 1152-60.
16. EMEA. European Public Assessment Report on Exelon. http://www.emea.eu. int/humandocs/Humans/EPAR/exelon/Exelon.htm2004 (last accessed: 24 February 2006).
17. Coomarasamy A, Knox EM, Gee H, Khan KS. Oxytocin antagonists for tocolysis in preterm labour - a systematic review. Med Sci Monit 2002; 8: RA268-RA273.
18. EMEA. European Public Assessment Report on Temodal. http://www.emea.eu. int/humandocs/Humans/EPAR/Temodal/Temodal.htm2004 (last accessed: 24 February 2006).
19. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
20. DeAngelis LM. Chemotherapy for brain tumors - a new beginning. N Engl J Med 2005; 352: 1036-8.
21. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai HM. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-7.
22. McCarthy MW, Kockler DR. Clopidogrel-associated leukopenia. Ann Pharmacother 2003; 37: 216-9.